A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV).

Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Lamivudine; Lopinavir; Nelfinavir; Ritonavir; Stavudine

Criteria

Inclusion Criteria

You may be eligible for this trial if you:

• Are HIV positive.

• Have a viral load (level of HIV in your blood) of more than 400 copies/ml.

• Are age 12 or older.

• Agree to practice abstinence or use effective methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this trial if you:

• Have taken anti-HIV drugs for more than 14 days in the past, or if you have ever taken d4T or 3TC.

• Are seriously ill or have an AIDS-related infection.

• Are pregnant or breast-feeding.

• Are taking certain medications.